KARUNA THERAPEUTICS INC (KRTX)

US48576A1007 - Common Stock

329.83  +0.09 (+0.03%)

After market: 329.83 0 (0%)

News Image
2 months ago - Seeking Alpha

Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb

Karuna Therapeutics (KRTX) experienced a temporary stock decline of 7.6%, but has since recovered to a 2% loss.

News Image
2 months ago - Seeking Alpha

Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29 (NASDAQ:KRTX)

Karuna Therapeutics reports Q4 financial results, with a GAAP EPS of -$3.01, missing expectations by $0.29.

News Image
2 months ago - InvestorPlace

Mental Health Mavericks: 3 Stocks Changing the Game

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

News Image
3 months ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMGI, KRTX, SIX, AVRO

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
3 months ago - Seeking Alpha

Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)

Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.

News Image
3 months ago - Halper Sadeh LLP

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CVLY, PGTI, KRTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
3 months ago - Seeking Alpha

Karuna’s KarXT tops Evaluate’s most anticipated drug list (NYSE:BMY)

Evaluate Vantage ranks Karuna Therapeutics' (KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.

News Image
3 months ago - Seeking Alpha

Karuna’s KarXT is Evaluate's most anticipated drug for 2024

Evaluate Vantage ranks Karuna Therapeutics'(KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.

News Image
3 months ago - Halper Sadeh LLP

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates KRTX, RYZB, VIA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
3 months ago - Seeking Alpha

Bristol-Myers almost lost Karuna buyout to third party (NYSE:BMY)

Bristol Myers Squibb (BMY) successfully fought to acquire Karuna Therapeutics (KRTX) in a $14B deal, outmaneuvering another large pharma bidder. Read more here.

News Image
4 months ago - Halper Sadeh LLP

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates ICVX, CVLY, PGTI, KRTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
4 months ago - Seeking Alpha

Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)

Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping

News Image
4 months ago - Kuehn Law, PLLC

Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
4 months ago - Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

News Image
4 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RYZB, KRTX, GRCL

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
4 months ago - Seeking Alpha

Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)

Bank of America downgrades Bristol-Myers Squibb (BMY) to Neutral due to concerns over upcoming patent expiries. Read more here.

News Image
4 months ago - Seeking Alpha

What's in store for biotech M&A and IPOs in 2024? (NYSE:BMY)

Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.

News Image
4 months ago - Investor's Business Daily

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review

The major indexes boast big annual gains with the Dow at record highs.

News Image
4 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...